VACCINI | COMIRNATY – MRNA BNT162B2 | PFIZER/BIONTECH
- New England Journal of Medicine, 30 marzo 2022 | “BNT162b2 Protection against the Omicron Variant in Children and Adolescents”
- New England Journal of Medicine, 23 marzo 2022 | “Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine”
- MMWR, 11 marzo 2022 | “Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022”
- New England Journal of Medicine, 24 febbraio 2022 | “Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents”
- New England Journal of Medicine, 26 gennaio 2022 | “SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination”
- New England Journal of Medicine, 16 febbraio 2022 | “Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19”
- New England Journal of Medicine, 26 gennaio 2022 | “Myocarditis after BNT162b2 Vaccination in Israeli Adolescents”
- New England Journal of Medicicne, 12 gennaio 2022 | “Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents”
- New England Journal of Medicine , 29 dicembre 2021 | “Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa”
- MMWR, 7 gennaio 2022 | “Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021”
- New England Journal of Medicine, 29 dicembre 2021 | “Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection”
- New England Journal of Medicine , 23 dicembre 2021 | “BNT162b2 Vaccine Booster and Mortality Due to Covid-19”
- New England Journal of Medicine, 23 dicembre editoriale | ” Booster Doses and Prioritizing Lives Saved”
- New England Journal of Medicine, 23 dicembre 2021 | “Protection against Covid-19 by BNT162b2 Booster across Age Groups”
- New England Journal of Medicine, 8 dicembre 2021 | “BNT162b2 Vaccine Booster and Mortality Due to Covid-19”
- New England Journal of Medicine, 8 dicembre 2021 | “Protection against Covid-19 by BNT162b2 Booster across Age Groups”
- New England Journal of Medicine, 2 dicembre 2021 | “Myocarditis after Covid-19 Vaccination in a Large Health Care Organization”
- New England Journal of Medicine, 2 dicembre 2021 | “Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel”
- New England Journal of Medicine, 25 novembre 2021 | “Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents”
- JAMA Internal Medicine, 30 novembre 2021 | “Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine”
- JAMA, 21 novembre 2021 | “Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older”
- New England Journal of Medicine, 9 novembre 2021 |“Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age”
- New England Journal of Medicine , 4 novembre 2021 |“Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months”
- The Lancet, 29 ottobre 2021 |“Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study”
- MMWR, 22 ottobre 2021 | “Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021
- New England Journal of Medicine, 6 ottobre 2021 | “Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months”
- New England Journal of Medicine, 6 ottobre 2021 | “Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar”
- New England Journal of Medicine. 15 settembre 2021 | ”Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months”
- New England Journal of Medicine, 25 agosto 2021 | “Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting”
- New England Journal of Medicine, 14 luglio 2021 | “Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents”
- New England Journal of Medicine, editoriale 25 agosto 2021 | “The Importance of Context in Covid-19 Vaccine Safety”
- New England Journal of Medicine , 1 luglio 2021 | “SARS-CoV-2 Antibody Response in Persons with Past Natural Infection”
- New England Journal of Medicine, 28 maggio 2021 | “Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents”
- MMWR, 14 maggio 2021 | “The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021”
- JAMA, 6 maggio 2021 | ”Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers”
- JAMA, 6 maggio 2021 | “Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce”
- The Lancet Oncology, 27 aprile 2021 | “ Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study”
- JAMA, 15 aprile 2021 | “Spike Antibody Levels of Nursing Home Residents With or Without Prior COVID-19 3 Weeks After a Single BNT162b2 Vaccine Dose”
- New England Journal of Medicine, 15 aprile 2021 | “BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting”
- New England Journal of Medicine, 14 aprile 2021 | “SARS-CoV-2 Antibody Response in Persons with Past Natural Infection”
- New England Journal of Medicine, 8 aprile 2021 | “Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2”
- Nature Medicine, 29 marzo 2021 | “Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine”
- New England Journal of Medicine, 23 marzo 2021 | “Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine”
- New England Journal of Medicine, 8 marzo 2021 | “Neutralizing Activity of BNT162b2-Elicited Serum”
- FDA, 25 febbraio 2021 | “Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine”
- The Lancet, 25 febbraio 2021 | “Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine”
- New England Journal of Medicine, 24 febbraio 2021 | “BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting”
- New England Journal of Medicine, 17 febbraio 2021 | “Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report”
- The Lancet, 18 febbraio 2021 | “Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients”
- Jama, 12 febbraio 2021 | “Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021”
- Science, 29 gennaio 2021 | “Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera”
- AIFA, 29 gennaio 2021 | “Primo aggiornamento EMA sulla sicurezza di Comirnaty”
- JAMA, 21 gennaio 2021 | “Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine”
- MMWR, 6 gennaio 2021 | “Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020”
- AIFA, 22 dicembre 2020 | “Vaccinazione anti COVID-19 con vaccino Pfizer mRNABNT162b2 (Comirnaty)” – FAQ AIFA
- FDA, 11 dicembre 2020 | “FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine”
- New England Journal of Medicine, 10 dicembre 2020 | “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine”
- New England Journal of Medicine, 10 dicembre 2020 | “SARS-CoV-2 Vaccination — An Ounce (Actually, Much Less) of Prevention” Editorial to original article “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine”
- Nature, 9 novembre 2020 | “What Pfizer’s landmark COVID vaccine results mean for the pandemic”
- New England Journal of Medicine, 14 ottobre 2020 | “Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates”
- New England Journal of Medicine, 29 settembre 2020 | “Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults”